GlaxoSmithKline (NYSE:GSK) has been assigned a $38.00 price objective by equities researchers at Cowen in a research note issued on Monday. The brokerage currently has a “hold” rating on the pharmaceutical company’s stock. Cowen’s target price points to a potential upside of 8.05% from the stock’s current price.
A number of other equities analysts have also recently commented on GSK. TheStreet raised shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a research note on Wednesday, October 25th. UBS raised shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $35.04 to $35.85 in a research note on Monday, November 27th. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Wednesday, October 18th. Argus reissued a “buy” rating and issued a $50.00 price objective on shares of GlaxoSmithKline in a research note on Thursday, August 31st. Finally, Investec cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Monday, November 6th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $39.37.
GlaxoSmithKline (GSK) traded up $0.33 on Monday, reaching $35.17. 4,530,500 shares of the company traded hands, compared to its average volume of 3,524,805. The stock has a market capitalization of $86,495.23, a PE ratio of 12.47, a price-to-earnings-growth ratio of 1.95 and a beta of 0.98. GlaxoSmithKline has a 52 week low of $34.52 and a 52 week high of $44.53. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96.
Several institutional investors have recently added to or reduced their stakes in GSK. FinTrust Investment Advisory Services LLC bought a new stake in GlaxoSmithKline during the 3rd quarter valued at about $401,000. Freestone Capital Holdings LLC lifted its holdings in GlaxoSmithKline by 11.9% during the 2nd quarter. Freestone Capital Holdings LLC now owns 94,008 shares of the pharmaceutical company’s stock valued at $4,054,000 after buying an additional 10,017 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in GlaxoSmithKline by 112.1% during the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after buying an additional 4,935,900 shares in the last quarter. Fulton Bank N.A. lifted its holdings in GlaxoSmithKline by 4.9% during the 3rd quarter. Fulton Bank N.A. now owns 75,269 shares of the pharmaceutical company’s stock valued at $3,056,000 after buying an additional 3,515 shares in the last quarter. Finally, First Bank & Trust lifted its holdings in GlaxoSmithKline by 20.8% during the 3rd quarter. First Bank & Trust now owns 44,540 shares of the pharmaceutical company’s stock valued at $1,808,000 after buying an additional 7,673 shares in the last quarter. Hedge funds and other institutional investors own 9.83% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cowen Reiterates “$38.00” Price Target for GlaxoSmithKline (GSK)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/11/cowen-reiterates-38-00-price-target-for-glaxosmithkline-gsk.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.